ArticleNPJ vaccines2026
Efficacy of the meningococcal vaccine against Neisseria gonorrhoeae: a randomised clinical trial (MenGO).
Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- An mRNA-Lipid Nanoparticle Platform Encoding the Conserved Outer Membrane Protein BamA Elicits Broadly Cross-Reactive Systemic and Mucosal Antibodies Against Antimicrobial-ResistantbioRxiv : the preprint server for biology · 2026Article
- A Decade of the Global STI Vaccine Roadmap: Progress, Gaps and Challenges.Journal of the International AIDS Society · 2026Article
- Discovery and characterization of an anti-Frontiers in microbiology · 2026Article
- Pre-clinical efficacy of a C4BP hexameric IgG Fc fusion protein against Neisseria gonorrhoeae.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neisseria gonorrhoeae (NG) causes significant morbidity globally, and no licensed vaccine currently exists. Observational studies suggest the four-component meningococcal B (4CMenB) vaccine may provide cross-protection against NG. We conducted MenGO, an open-label, randomized controlled trial to evaluate the efficacy, safety, and immunogenicity of 4CMenB against NG in gay and bisexual men (GBM). Participants were randomized 1:1 to receive two doses of 4CMenB, or no vaccine, and were followed for 2 years with 3-monthly visits. 4CMenB vaccination did not significantly reduce gonorrhoea incidence (incidence rate ratio 0.78 (95% confidence interval (CI) 0.40-1.51;p = 0.457), and no study-related serious adverse events occurred. The vaccine was immunogenic against NG, with higher serum bactericidal activity (hSBA) median titres at 6 months in vaccinated compared to unvaccinated participants (4 [interquartile range (IQR) 2-8] vs 2 [IQR 2-2];p = 0.0021). However, hSBA titres did not increase in participants with an NG infection at the time of vaccination (2 [IQR 2-2] to 2 [IQR 2-4];p = 0·999), whereas those without NG infection showed an increase from baseline to 6 months (2 [IQR 2-4] to 6 [IQR 2-16];p = 0.0089). This study is limited by its small sample size based on an assumed vaccine efficacy of >67% and was impacted by the COVID-19 pandemic. These findings provide important information for current 4CMenB vaccines programmes and gonorrhoea vaccine development and implementation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.